Tenofovir Alafenamide Promotes Differentiation and Induces Apoptosis of AML Cells by Inhibiting Telomerase Reverse Transcriptase

View at publisher Summarise with VIRAT
Authors: JI-EUN LEE, Byeol-Eun Jeon, Chan-Seong Kwon, Su-Ji Lee, Youngseob Seo, Ho‐Jin Shin, Sang‐Woo Kim
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND/AIM: Acute myeloid leukemia (AML) is the most common type of leukemia in adults. However, patient prognosis remains poor despite advances in our understanding of its molecular cytogenetics and pathogenesis. Differentiation therapy aims to overcome the characteristic differentiation blockade observed in leukemia cells, but its efficacy is limited to specific AML subtypes. Therefore, there is an urgent need to develop novel therapeutic agents for AML. MATERIALS AND METHODS: To identify potential therapeutic candidates, we screened 100 US Food and Drug Administration-approved drugs by measuring CD11b expression. The anti-leukemia effects of tenofovir alafenamide (TAF) were evaluated using flow cytometry, MTS assays, cell proliferation assays, and trypan blue staining in U937 and THP-1 AML cells. Real-time polymerase chain reaction was performed to assess the expression of differentiation-associated genes and relative telomere length. Western blotting was used to detect proteins involved in the DNA-damage response. RESULTS: Through chemical screening, TAF was identified as a drug with significant differentiation-inducing activity in AML cells. TAF promoted differentiation while simultaneously reducing cell viability and inhibiting cell proliferation. Moreover, TAF exhibited synergistic effects when combined with cytarabine. TAF also suppressed cell proliferation in primary AML patient samples harboring various mutations. Mechanistically, TAF inhibited telomerase reverse transcriptase activity and increased generation of reactive oxygen species, thereby activating the DNA-damage response. CONCLUSION: TAF may serve as a promising novel therapeutic agent for the treatment of AML.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Telomeres Telomerase and Senescence

Publication details

Journal / source
Anticancer Research
Volume
46
Issue
4
Pages
1943–1955
Publication date
27 March 2026
Language
EN